Building castles on sands or quicksands? The strengths and weaknesses of economic evaluation in pharmaceuticals.
Maynard
A
A
York Health Economics Consortium, University of York, USA. akm3@york.ac.uk
Bloor
K
K
D003024:Clozapine / Q000191:economics / Q000627:therapeutic use; D003657:Decision Making; D016527:Drug Costs; D017048:Health Care Costs; D006291:Health Policy / Q000191:economics; D006801:Humans; D017410:Practice Guidelines as Topic; D015397:Program Evaluation; D018967:Risperidone / Q000191:economics / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy / Q000191:economics*
D003024:Clozapine; D018967:Risperidone